Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder - PubMed (original) (raw)

Review

Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder

Carlos A Zarate et al. CNS Drugs. 2009.

Abstract

Bipolar disorder is one of the most severely debilitating of all medical illnesses. For a large number of patients, outcomes are quite poor. The illness results in tremendous suffering for patients and their families and commonly impairs functioning and workplace productivity. Risks of increased morbidity and mortality, unfortunately, are frequent occurrences as well. Until recently, little has been known about the specific molecular and cellular underpinnings of bipolar disorder. Such knowledge is crucial for the prospect of developing specific targeted therapies that are more effective and that have a more rapid onset of action than currently available treatments. Exciting recent data suggest that regulation of certain signalling pathways may be involved in the aetiology of bipolar disorder and that these pathways may be profitably targeted to treat the disorder. In particular, mania is associated with overactive protein kinase C (PKC) intracellular signalling, and recent genome-wide association studies of bipolar disorder have implicated an enzyme that reduces the activation of PKC. Importantly, the current mainstays in the treatment of mania, lithium (a monovalent cation) and valproate (a small fatty acid) indirectly inhibit PKC. In addition, recent clinical studies with the relatively selective PKC inhibitor tamoxifen add support to the relevance of the PKC target in bipolar disorder. Overall, a growing body of work both on a preclinical and clinical level indicates that PKC signalling may play an important role in the pathophysiology and treatment of bipolar disorder. The development of CNS-penetrant PKC inhibitors may have considerable benefit for this devastating illness.

PubMed Disclaimer

Figures

Fig. 1

Fig. 1

Protein kinase C (PKC) in the pathophysiology and treatment of manic behaviour. DA = dopamine; GAP-43 = growth-associated protein of 43 kDa; NA = noradrenaline (norepinephrine); ↑ indicates increased.

Fig. 2

Fig. 2

Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study design and dose escalation.

Fig. 3

Fig. 3

Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study (reproduced from Zarate et al.[55]). Tamoxifen vs placebo: * p < 0.05 after correction. Week vs baseline for tamoxifen: * p < 0.05, ** p < 0.01, *** p < 0.001 after correction. YMRS = Young Mania Rating Scale.

Similar articles

Cited by

References

    1. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007;64 (5):543–52. - PMC - PubMed
    1. Gitlin M. Treatment-resistant bipolar disorder. Mol Psychiatry. 2006;11 (3):227–40. - PubMed
    1. Manji HK, Zarate CA. Molecular and cellular mechanisms underlying mood stabilization in bipolar disorder: implications for the development of improved therapeutics. Mol Psychiatry. 2002;7 (Suppl 1):S1–7. - PubMed
    1. Zarate CA, Jr, Singh J, Manji HK. Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry. 2006;59 (11):1006–20. - PubMed
    1. Casabona G. Intracellular signal modulation: a pivotal role for protein kinase C. Prog Neuropsychopharmacol Biol Psychiatry. 1997;21 (3):407–25. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources